priyaraut's blog

E-health services Market Overview by types, by service, by end user, Forecast to 2030. The e-health services are relatively recent healthcare practices that include incorporation of electronic processes and communication systems. The rapid adoption of advanced technology in various sectors is augmenting the utilization of such services all over the world.

Market Research Future (MRFR) has recently availed a detailed report asserting the E-Health Services Market is projected to reach USD 8,905 Million by 2030 at 18.50% CAGR during the forecast period 2022-2030.

Market Drivers and Restraints:

The rapid technological development is playing a crucial role in the expansion of the global e-health services market. The rise in adoption of advanced technology in the healthcare sector is acting as a major driver for the expansion of the global e-health services market. The increasing government initiatives for supporting the use of e-health services in healthcare sector and emergence of curtailing the escalating healthcare costs are attributing factors to the growth of the global e-health services market.

Various regions in the world are facing a shortage of healthcare professionals and high prevalence of chronic diseases, leading to the growing need for e-health services in such regions. The shift in focus of the players of healthcare sector towards providing patient-centric healthcare facilities is fueling the expansion of the global e-health services market. The brisk advancement in technology has led to the increased adoption of cloud computing in the various industrial sectors, including healthcare, which in turn is driving the global e-health services market. 

The prominent players of the global e-health services market are IBM Corporation (U.S), Allscripts Healthcare Solutions Inc. (U.S), GE Healthcare (U.S), McKinsey & Co. (U.S), Motion Computing Inc. (U.S), Epocrates Inc. (U.S), Telecare Corp. (U.S), Proteus Digital Health (U.S) Apple (U.S), GE Healthcare (U.S), Boston Scientific Corp (U.S), and Cerner (U.S). 

The benefits of e-health services such as minimum errors, large data storage and easy access, reliable EHR and EMR services, secure data sharing, and others are resulting in the incorporation of e-health services in the healthcare sector, which is driving the global e-health services market. The global e-health service market is also observed to be flourishing owing to the increased application of ICT for clinical and financial data handling in various hospitals and clinics. 

On the flipside, the high cost of installation and maintenance of the services, reluctance towards the adoption of advanced e-health services among medical professionals, lack of basic healthcare infrastructure in underdeveloped regions, and privacy and security concerns among the patients are likely to hamper the growth of the global e-health service market to some extent.

Market Segmentation:

The global e-health services market has been segmented on the basis of type, service, and end-users. By type, the global e-health services market is segmented into electronic health records (EHR), e-prescribing, telemedicine, big data systems, clinical decision support system (CDSS), mobile medical technologies, consumer health IT, and knowledge management system (KMS). By service, the market is segmented into administrative service, clinical service, and financial service. By end-users, the market is segmented into hospitals, clinics, health insurance companies and others.

Detailed Regional Analysis:

The global e-health services market research report is geographically distributed in for major regions such as Americas, Europe, Asia-Pacific and the Middle East and Africa. Among these regions, the North America region is considered to be the largest market for the e-health services due to the concentration of major players of global e-health services market in this region, the inclination towards the use of software for data management and the presence of well-developed healthcare infrastructure in this region.  

The rapid adoption of advanced technology in the healthcare sector of the Europe region has made it the second largest market for the e-health services among other regions of the world. Whereas, the Asia-Pacific region is projecting fastest growth in the global e-health services market owing to the rapid development and adoption of advanced technology by healthcare sector in this region. 

The e-health services market in the Middle East and Africa region is projecting steady growth due to lack of technological awareness and poor healthcare infrastructure in the underdeveloped areas of this region.  

Competitive Analysis:

The increase in research and development expenditure and focus on strategic mergers and acquisitions by the leading players of the global e-health services market is strengthening the competition among the players of the global market.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Downstream Processing Market trends was valued at USD 21.5 billion in 2022 and is projected to grow from USD 24.95 Billion in 2023 to USD 61.09 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.09% during the forecast period (2023 - 2030). Downstream processing refers to the series of operations required to derive pure and homogeneous protein products from biological materials such as cells, tissue culture fluid, or plant tissues. There is a high demand for the end products extracted by downstream processing, owing to the increasing applicationsin biopharmaceutical products. Thus, the downstream processing market is anticipated to observe significant growth during the forecast period.

Many market players are dominating the global downstream processing market. The prominent players are involved in strategic agreements,new product launches& developments,joint ventures, partnerships, collaborations, mergers & acquisitions, geographic expansionto sustaintheir market positions.For instance, in March 2021, Thermo Fisher Scientific, Inc. (US) announced that more than USD 600 million would be invested to expand its bioprocessing production capabilities through 2022 to meet short-term demands related to COVID-19 as well as long-term efforts to improve new vaccines and biologics for other conditions.

Key Players

Some of the key players in the global downstream processing market are Thermo Fisher Scientific Inc. (US), Sartorius Stedim Biotech S.A. (France), Merck Millipore (Germany), Danaher Corporation (US), 3M Company (US), Boehringer Ingelheim (Germany), Lonza Group AG (Switzerland), Eppendorf AG (Switzerland), Corning Incorporated (US), and Asahi Kasei Corporation (Japan).

Segmentation

The global downstream processing market has been segmented into technique, product, application, and end user.

By technique, the market has been segregated into cell disruption, solid-liquid separation, clarification/concentration, downstream purification techniques, and formulation. The purification techniques segment is further sub-segmented into ion exchange, affinity exchange, hydrophobic interaction, size exclusion chromatography, and others. The purification techniques segment held a significant share of the market in 2020, as it isone of the vital steps in downstream processing and has high product differentiation.

Based on the product, the global downstream processing market has been classified as chromatography columns &resins, filters, membrane adsorbers, and others. The chromatography columns &resinsis one of the most widely used product andwasestimated to bethe largest segment in 2020.

Based on application, the downstream processing market is segmented into antibiotic production, hormone production, antibodies production, vaccine production, and others. Antibiotic productionis one of the vital applications owing to increasing infectious diseases. Furthermore, the ongoing pandemic has created a huge demand for vaccine production globally which further supports the growth of the market.

Based on the end user, the downstream processing market is segmented into biopharmaceutical manufacturers, contract manufacturing organizations, and others. The biopharmaceutical manufacturers segment held the largest market share in 2020 due to increased R&D activities and production of biologics at a largescale, along with the rapidly growing biopharmaceutical industry.

Regional Analysis

By region, North America is anticipated to dominate the global downstream processing market report, owing to well-established research organizations involved in research activities, the presence of a high number of contract manufacturing organizations (CMOs), and the presence of a largenumber of pharmaceutical and biopharmaceutical companies. Moreover, the rise in R&D investments by public and private players in the healthcare sectorfurther drives the market growth.

On the other hand, the European downstream processing market is driven by rising R&D expenditure by biopharmaceutical companies, increasing investments in the R&D sector, and the presence of key market players. For instance, in November 2019, Thermo Fisher Scientific, Inc. (US) announced that it is investing nearly USD 24 million in its Scotland site to expand global bioproduction capabilities with additional large-volume liquid manufacturing capacity for cell culture media.

Asia-Pacific is anticipated to be the fastest-growing market in the region over the assessment period due to growing and improving healthcare infrastructure, the establishment of research organizations, and increasing investments in biotechnology. In addition, factors such as the growing investments by key market players and the rapidly developing pharma and biopharma sector in the region are further driving the market.For instance, in April 2021, Asahi Kasei Corporation, a solution provider to the biologics manufacturing industry, expanded its business in China with the launch of Asahi Kasei Bioprocess (Shanghai) Co., Ltd (AKBC).The launch of AKBC facilitates business expansion in China by localizing inventory management and order processing for shorter delivery times.

Furthermore, the growth of the market in theRest of the World is attributed to the booming biotechnology sector and advancements in chromatographic techniques inthe region.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

The anticoagulation market trends is expected to cross USD 20.54 Billion by 2030 at a CAGR of 7.50% during the forecast period. The global Anticoagulation Market is growing steadily due to the rising demand for anticoagulants, which creates lucrative growth opportunities for the number of players coming forward with new and better products. The value chain analysis of the market comprises four major components: research & development and designing, manufacturing the products, distribution & sales, and post-sales services.

Research &development start with conceptualizing, followed by design, then development, and lastly, testing. The R&D segment comprises 25-30% of the value chain. After the product designs are final, the manufacturing of the product starts. Manufacturing consists of 45-50% of the value chain. Then comes distribution and sales, which is essential for any industry.

Key Players

Anticoagulation Market Players are Pfizer Inc (US), Sanofi (France), Novartis AG (Switzerland), GlaxoSmithKline plc (UK), Daiichi Sankyo Company, Limited, Inc. (Japan), Johnson & Johnson Services Inc (US), Boehringer Ingelheim International GmbH (Germany), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd (Switzerland), and Portola Pharmaceuticals, Inc (US).

Market Segmentation

The global anticoagulation market is segmented into drug class, route of administration, disease indication, distribution channel, and region. The drug class segment has been further segmented into direct oral anticoagulants (DOACs), warfarin, vitamin K, and heparins & Low Molecular Weight Heparin (LMWH). The disease indication segment is further segmented into heart attacks, stroke, Deep Vein Thrombosis (DVT)/Pulmonary Embolism (PE), Mechanical Heart Valves (MHV), and others. The route of administration segment has been further segmented into oral, injectable, andothers. The distribution channel segment is segmented into retail pharmacies, hospital pharmacies, andonline pharmacies.

Regional Analysis

The global anticoagulation market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World.

The North American market accounted for the largest share in 2019 and is expected to increase at a CAGR of 8.20% during the forecast period. This is due to the rising prevalence of venous thromboembolism (VTE) and cardiovascular disorders, increased risk of a blood clot in various medical conditions, and the adoption of NOACs globally. According to a published article in PubMed in 2019, NOACs have emerged as promising alternatives to Vitamin K Antagonists (VKAs). However, there are some considerations and challenges to their introduction in developing countries.

Europe accounted for a market size of USD 5,205.37million in 2019 and is expected to grow at a CAGR of 7.26% during the forecast period. It has evolved as a prominent market with increased cardiovascular diseases and rising investments in R&D in the pharmaceutical sector. The region has considerable growth potentials that would help expand the global market in the coming years. However, stringent regulations set by various governments are hampering the market growth in the European region.

The anticoagulation market research Report in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. Asia-Pacific is expected to showthe highest growth rate during the forecast period from 2020 to 2027. Factors such as an increasing patient population suffering from various chronic and acute diseases, rising prevalence of cardiovascular disease and VTE, developing economies, improving diagnosis rate, and growing demand for ideal therapeutics are anticipated to boost the market growth. Furthermore, continuous economic development with evolving healthcare infrastructure and improving healthcare awareness have further supported the market's growth. However, increasing treatment expenditure for anticoagulant drugs is anticipated to hamper the market growth in the Asia-Pacific region.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

According to MRFR analysis, The Cell Counting Market size is expected to cross USD 14.56 Billion by 2030 at a CAGR of 7.8% during the forecast period 2022-2030.

Cell counting is important for research and serves as one of the major steps in the majority of experiments. It is effectively utilized for maintaining cell cultures. Moreover, another important application of cell counting can be seen in the diagnosis of chronic diseases like cancer. For instance, an increase in the number of white blood cells (WBC) may indicate the possibility of cancerous growth in the body. Thus, cell counting is important for microbiology, hematology and other medical specialties.

The growth of the global cell counting market is determined by numerous factors such as increasing R&D expenditure, rising prevalence of cancer, and product launches. However, the high cost of devices and product recalls are projected to restrain the growth of the market during the forecast period.

The Global Cell Counting Market is currently dominated by several market players. The key players are involved in product launches, expansion, and strategic collaborations to strengthen their market positions. Recently in April 2019, the Nexcelom Bioscience LLC launched Cellaca MX automated cell counter.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is anticipated to hold the largest market share owing to the increase in the incidence of cancer and the presence of well-established pharmaceutical and biotechnology industry. The cell counting market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.

The European cell counting market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The cell counting market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the presence of a large patient pool and expansion of healthcare facilities, the market in Asia-Pacific is expected to be the fastest-growing. The cell counting market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The Global Cell Counting Market Insights has been segmented based on product, application, and end-user.

The market, based on type, has been divided into consumables and instruments. The consumable segment is likely to hold maximum market share in the global cell counting market. This due to the repeated purchase of the consumable compared with instrument products.

The global cell counting market based on application has been segregated into research application, clinical & diagnostic application, and others. The research application segment is anticipated to hold the largest share in the market due to the rising funding for stem cell research.

The end-user segments of the market are pharmaceutical and biotechnology companies, hospitals, research institutes, and others. The pharmaceutical and biotechnology companies’ segment is expected to hold the largest share of the market, as these are used cell counting products in research and development of new drugs and therapies.

Key Players

Some of the Key Players in the Global Cell Counting Market are Thermo Fisher Scientific (US), Merck KGaA (Germany), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Logos Biosystems, Inc. (South Korea), Olympus Corporation (Japan), Agilent Technologies, Inc. (US), PerkinElmer, Inc. (US), Sysmex Corporation (Japan), Abbott Laboratories (US), and others.

Preimplantation Genetic Testing Market Overview and Analysis by Procedure, Type, Application, Technology and forecast to 2030. It is estimated that the global preimplantation genetic testing market is grow USD 545.8 Million in 2030 and is projected to register a CAGR of around 10.20% over the forecast period 2022-2030.

Preimplantation genetic testing is the testing at the pre-implantation stage for detection of genetic defects in embryos or oocytes. Preimplantation genetic testing has occurred more frequently in recent years in North America and Europe, due to the advancement in genetic technology.

The decreasing fertility rates worldwide enhance the acceptance of the preimplantation genetic testing to avoid further complications of chromosomal abnormalities with advancing maternal age. This leads to the growth of the genetic testing for rare diseases during the forecast period. According to the Vital Statistics Rapid Release, the total fertility rate for the US in 2017 was 1,764.5 births per 1,000 women, and in 2016 it was 1,820.5,  which is 3% less, this shows the reduction in the rate of fertility.

An increasing number of fertility clinics worldwide, new development technological advancements in the field of genetic analysis and high threat of chromosomal abnormalities with advancing maternal age are the other driving factors for global preimplantation genetic testing market

Key Players

Some of the major players in the global preimplantation genetic testing market are Natera, Inc.CooperSurgical, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., IGENOMIX, Reprogenetics, LLC, Genea Limited, PerkinElmer, Inc., Genesis Genetics Ltd., Quest Diagnostics Incorporated, Thermo FisherScientific, Inc, Bioarrayn Genetics, Laboratory Corporation of America Holdings, California Pacific Medical Center and Reproductive Health Science Ltd

Segmentation

The global preimplantation genetic testing market is segmented based on procedure, type, application, technology, product and service, end user, and region.

The global market for preimplantation genetic testing, by procedure, is segmented into preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS). Hundred different genetic conditions can be tested with Preimplantation Genetic Diagnosis (PGD) which enables the couple to have a baby with no genetic defect thus the segment is expected to hold the largest market share owing to rising awareness population and healthcare experts. Preimplantation Genetic Screening (PGS) segment is also anticipated to grow profitably to increase healthy pregnancy.

By type, embryo testing segment is expected to show favorable growth as the threat of chromosomal abnormalities increases. By product and service, the reagents and consumables segment anticipated to hold the largest market share as there is continuous declination infertility of female due to increasing usage of reagents for the diagnosis. By technology, the next-generation sequencing segment, and comparative genomic hybridization also expected to hold large share as its cost is reduced and its capability to detect mosaicism. The market by end user has been segmented into maternity centers & fertility clinics

hospitals, diagnostic labs and research laboratories & academic institutes.  Based on region, the global preimplantation genetic testing market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The global preimplantation genetic testing market research report in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European global preimplantation genetic testing market has been sub-divided Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe. The global preimplantation genetic testing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The IPF treatment market in the Middle East & Africa has been divided into the Middle East and Africa.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

The minimally-invasive surgery devices market trends is expected to reach USD 26165.04 Million by 2030 at 9.20% CAGR during the forecast period 2022-2030. The minimally invasive surgery devices market is gaining traction due to increasing geriatric population and increasing prevalence life-threating and chronic diseases. The minimally invasive surgeries are less traumatic and comparatively safer, which makes the healing process faster and less painful. As per the World Health Organization (WHO), the prevalence of chronic diseases is estimated to escalate by 60% by the end of 2020 and 79% of the deaths are caused due to these diseases especially in developing countries. 

These surgeries are increasingly evolving in the field of ophthalmic, orthopedic, cardiac, oral surgical, and neurological procedures. Thanks to the continuous advancements in the surgical procedures makes it the more efficient and accurate, which boosts their adoption substantially.

Additionally, increasing awareness about benefits of the minimally invasive procedures is creating demand and is estimated to remain same in coming years. Further, rising popularity of robotic and non-robotic minimally invasive surgeries are fueling growth of the global minimally invasive surgery devices market. 

Increasing inclination toward the personal aesthetics, the demand for cosmetics and plastic surgeries are boosting adoption of minimally invasive surgeries, which in turn drives the growth of the minimally invasive surgery devices market. As per reports by the American Society of Plastic Surgeons, around 15.4 million cosmetic procedures were performed with minimally invasive surgical procedures in 2016. However, stringent government regulations coupled with high cost of surgery devices are restraining market growth. Nonetheless, the cost of these procedures is less than conventional surgeries which are likely to offer most lucrative opportunities for growth in coming years. 

Competitive Analysis:

Some of the key players operating in the global minimally invasive surgery devices market are Abbott, Medtronic, Inc, GE Healthcare, Ethicon, Inc., Siemens Healthcare GmbH, Intuitive Surgical, Inc, ArthroCare Corporation, NuVasive, Inc., DePuy Synthes, Biomet, Inc, KEBOMED Europe AG, Norwood Medical, Fortimedix Surgical, and Freudenberg Medical. 

Segmentation:

The minimally invasive surgery devices market report is segmented based on type, application, end-user, and region.

In terms of type, the global minimally invasive surgery devices market is categorized into handheld instruments, cutter instruments, inflation devices, guiding devices, auxiliary devices, electrosurgical devices, and others.

In terms of application, the minimally invasive surgery devices market is segmented into cardiac surgery, orthopedic surgery, gastrointestinal surgery, vascular surgery, urological surgery, gynecological surgery, thoracic surgery, dental surgery, cosmetic surgery, and others.

In terms of end-user, the minimally invasive surgery devices market is segmented into ambulatory surgical centers, hospitals & clinics, and others.

As per the region, the minimally invasive surgery devices market is segmented into Americas, Asia-Pacific, Europe, and the Middle East & Africa.

Regional Analysis:

Regionally, the Americas is estimated to dominate the global minimally invasive surgery devices market owing to large patient pool, high healthcare investment, and well-developed infrastructure. Additionally, growing government funding backing for adoption of advanced healthcare facilities for the several life-threating diseases are benefiting growth of the global minimally invasive surgery market. The market in Europe is estimated to secure second leading position in terms of revenue. 

However, Asia Pacific is predicted to expand at a highest CAGR in coming future due to substantial rise in patient pool, presence of large population, growth in government investments. Rise in geriatric population which is prone for several diseases which creates need for development of better facilities in the region. Additionally, emerging economies in the region are investing more for improvement in healthcare infrastructure and adoption of advanced surgical devices.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Opioids are medications prescribed by doctors and physicians to treat various levels of pain. These can include acute pain and chronic non-cancer pain. They are also known as painkillers and used to block pain signals from the brain. Market Research Future (MRFR) has stressed the advantages of the intake of opioids as well as the efforts by manufacturers to address various issues concerning the drugs. 

Growth Drivers

The opioids market is expected to reach USD 6,060.17 million at CAGR of 4.90% during the forecast period 2022-2030. Pain management of various chronic diseases remain the primary driver of the market. According to the National Institute of Drug Abuse, nearly 200 million prescriptions were dispensed by U.S. pharmacies in 2017. The large number of prescriptions is an indicator for the large scope of the market.

Favorable reimbursement schemes for covering the costs of opioids in palliative care can work in favor of the market. Large number of patients diagnosed with various cancers can drive the market demand for opioids till 2023. Rise in surgical procedures and road accidents are other factors which can contribute to market demand due to the need for pain relievers. All of these factors are predicted to push the market to exhibit a CAGR of 7.12% during the forecast period. 

Establishment of new guidelines to curb the intake of opioids and reduce the addiction rates are expected to disrupt the market in a positive manner. For instance, the sale of over-the-counter drugs containing opioids is restricted, while stringent measures are undertaken regarding prescriptions given by doctors. New policies by government-supported insurance companies such as Medicare are limiting the dispensation rate of opioids to 7 days.

But misuse of viatris opioids and adverse effects of the drugs which lead to addiction threaten the market growth. 

Segments In-Detail:

MRFR has segmented the global opioids market by product, application, and end-user. 

Based on the product, the market is segmented into immediate release/short-acting opioid and extended release/long-acting opioid. Extended release comprises hydromorphone, oxycodone, morphine, oxymorphone, and others. The extended release segment had accounted for USD 12,750.91 million in 2017. This segment can expand in the coming years due to rising prevalence of chronic diseases.

By application, it is segmented into diarrhea suppression, deaddiction, cough suppression, pain relief, anesthesia, and others. The pain relief segment is expected to be the dominant application of the opioids market due to rise in pain management therapies. Moreover, new guidelines for selling prescription drugs coupled with rise in palliative and end-of-life care can boost segment growth. This in turn can drive the market demand exponentially.

By end-user, the market caters to academic research institutes, hospitals & clinics, and pharmacies.

Regional Analysis:

MRFR’s report takes a deep look into major regions which include the Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA). 

The Americas is predicted to be dominant in the global market due to holding the largest market share due to awareness among patients and the high intake of the drugs for pain alleviation. On the other hand, Europe is expected to showcase prolific growth due to rise in palliative care centers and strict regulations regarding opioid usage.

A Look at the Competition:

Prominent companies operating in the opioids market players include Janssen Global Services, LLC, Egalet Corporation, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Sanofi SA, Purdue Pharma L.P, Boehringer Ingelheim GmbH, Allergan Inc., Sun Pharmaceutical Industries Ltd., Mallinckrodt, Vertice Pharma LLC, and West-Ward Pharmaceuticals Corporation. 

New in Research

Opioid-induced constipation is on the rise due to being one of the side-effects during intake of pain relievers. In 2019, Novartis has agreed to partner with Shinogi & Co Ltd, for bringing to market Rizmoic in selected areas of the Netherlands, the U.K., and Germany.

According to a study published by the researchers at the University of Pennsylvania School of Medicine, patients in the United States and Canada are more likely to procure opioids due to the large number of chronic diseases. High prevalence of minimally invasive surgeries and prescription of codeine in post-operative care can bode well for the global opioids market in the coming years.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Analysis
Dental Biomaterials Market Overview, by Type, by Application, by End User, Forecast till 2030. The dental biomaterials market is anticipated to reach USD 8720.26 Million by 2030 at 5.9% CAGR during the forecast period 2022-2030, reveals the new Market Research Future (MRFR) report. Dental biomaterials, simply put, are natural or fabricated structures that are utilized in dentistry for orthodontics, prosthodontics, implantology, and others. 

Various factors are propelling the dental biomaterials market growth. Such factors, as per the latest Market Research Future report, include the growing awareness about the significance of dental implants, rise in disposable income, rising investments in the dental industry, and growing dental tourism. Additional factors pushing the growth of the dental biomaterials market include increasing dental expenditure and increasing incidence of dental trauma and dental caries. 

On the contrary, scarcity of dental professionals, presence of strict clinical and regulatory processes, reported cases of peri-implant and peri-implantitis mucositis, and the soaring cost of implants are factors that may deter the dental biomaterials market growth during the forecast period.

Market Segmentation

The Market Research Future report provides an all-inclusive segmental analysis of the dental biomaterials market on the basis of end user, type, and application.

By type, the dental biomaterials market is segmented into natural biomaterials, metal-ceramic biomaterials, polymeric biomaterials, ceramic biomaterials, and metallic biomaterials. The metallic biomaterials segment is again segmented into chromium alloys, stainless steel, titanium, and others. Of these, metallic biomaterials will dominate the market during the forecast period. Various factors propelling the growth of the segment include its extensive applications in dentistry and rising penetration of dental implants. 

By application, the dental biomaterials market is segmented into orthodontics, prosthodontics, implantology, and others. Of these, the implantology segment will have the maximum share in the market during the forecast period. Various factors propelling the growth of the segment include the rising disposable income, growing dental tourism, bourgeoning demand for cosmetic dentistry, growing prevalence of dental diseases, high volume needs, and price of titanium used to manufacture dental implants, and rising penetration of dental implants worldwide. 

By end users, the dental biomaterials market is segmented into research institutes, dental academics, dental hospitals & clinics, dental laboratories, and dental product manufacturers. Of these, dental product manufacturers will lead the market during the forecast period. Various factors propelling the growth of the segment include the growing awareness of oral diseases, rising number of dental practices, growing adoption of CAM/CAD systems in laboratories and dental clinics, and increasing penetration of dental implants as well as prosthetics. 

 Regional Analysis

By region, the dental biomaterials market research report covers the latest trends and growth opportunities across the Americas, the Asia Pacific, the Middle East and Africa, and Europe. Of these, the Americas will lead the market during the forecast period. Factors pushing the growth of the dental biomaterials market in the region include evolving dental care infrastructure, highest diabetic population, early adoption of latest dental biomaterials, mounting prevalence and awareness of dental disorders, high dental expenditure, and presence of notable players in the region. China, as well as India, are the major contributors in the region.

The dental biomaterials market in Europe will have the second-largest share in the market during the forecast period. Factors pushing the growth of the dental biomaterials market in the region include rising government funding on oral healthcare, rising number of dental procedures, presence of various developed economies, increase in dental hospitals & clinics, growing geriatric population, and increasing use of dental biomaterials for manufacturing implants as well as other dental products. 

The dental biomaterials market in the APAC region will grow at the fastest pace during the forecast period. Factors pushing the growth of the dental biomaterials market in the region include growing awareness about oral health coupled with the rapidly developing dental industries. 

The dental biomaterials market in the MEA will have a minimal share during the forecast period owing to low healthcare expenditure, lack of awareness, and the presence of poor economies. 

Key Players

Notable players profiled in the dental biomaterials market report include Cam Bioceramics BV, Bego Medical GmbH, Datum Dental Ltd, Keystone Dental, Inc., GC Corporation, Ivoclar Vivadent AG, Victrex PLC, Mitsui Chemicals, Inc., Henry Schein, Inc., Medtronic PLC, Kuraray Co., Ltd, Carpenter Technology Corporation, Royal DSM, 3M Company, Dentsply Sirona, Inc., Danaher Corporation, Zimmer Biomet Holdings, Inc., Geistlich Pharma AG, and Straumann Holding AG. Key players have incorporated different strategies for sustaining the competitive environment, such as research and development for advancements in dental biomaterials, product approvals and product launches. 

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Clinical alarm management systems are likely to gain quick mileage in the foreseeable future. It has been assessed in a report published by Market Research Future (MRFR) that The clinical alarm management market size was valued USD 1.02 billion in 2021 and is expected to reach USD 5.35 billion by 2030 at 31.30% CAGR during the forecast period 2022-2030. These systems are non-invasive and send a warning to the doctors and nurses in case of emergencies. Increasing patient population is likely to fuel demand for these systems as it ensures efficiency and quick response to emergencies. 

The rising burden of chronic diseases has propelled the expansion of the clinical alarm management market and is poised to demonstrate a similar pattern in the years to come. Technological innovations by the key players are further expected to generate more demand in the nearby future, thus, catalyzing the growth of the global clinical alarm management market. It is also highlighted that the rising adoption of technology in the healthcare sector is benefitting the expansion of the clinical alarm management market over the next couple of years. However, factors such as sleep disruption and noise fatigue are anticipated to undermine the growth pace of the clinical alarm management market in the foreseeable future.

Regional Analysis:

For an extensive geographical assessment of the global clinical alarm management market, it has been segmented into four major regions – Americas, Europe, the Middle East & Africa (MEA), and Asia Pacific. Americas is currently holding the largest market share and is anticipated to maintain its prominence over the next couple of years. The developed healthcare infrastructure of the region is providing impetus to the expansion of the clinical alarm management market. Europe is poised to maintain its position at the second spot and is anticipated to benefit from the government support and funds. Asia Pacific clinical alarm management market is projected to register the highest CAGR over the assessment period. 

Market Segmentation:

The different segments, on the basis of products, identified in this study on the clinical alarm management market insights are segmented nurse call systems, EMR integration systems, physiological monitors, bed alarms, mobility solutions, ventilators, central monitoring systems, and clinical decision support tools.

The different components of the global clinical alarm management market assessed in this MRFR report are solutions and services.

On the basis of the end-user, the clinical alarm management market has been segmented into hospitals, ambulatory care centers & home care settings, and long-term care centers.

Competitive Dashboard:

The market exhibits robust competition among the key players on account of technological advancements. Since the technology is gaining momentum among the healthcare providers, participants in the global clinical alarm management market are anticipated to introduce innovative technologies for staying ahead of the curve. In addition, investments are expected to be increased in research and development for the development of product portfolios. This, in turn, is expected to impact revenue generation of the noted vendors favorably in the years to come.

Koninklijke Philips N.V., Vocera Communications, Medtronic, Baxter, Mindray Medical International, Ascom Holdings, Spok, Inc. (Subsidiary of Spok Holdings, Inc.), GE Healthcare, Masimo, Connexall, Drager, Capsule Technologie (Subsidiary of Qualcomm Life, Inc.), Bernoulli Enterprise, Inc., and Mobile Heartbeat (Subsidiary of Hospital Corporation of America) are some of the main players of the global clinical alarm management market and are poised to earn massive revenue in the upcoming years.

The market is also projected to make way for the entry of new players owing to the increasing number of technology startups venturing into the healthcare sector. The most promising strategies being adopted by the market participants for ensuring market growth are mergers & acquisitions, partnerships, product development, collaboration, etc.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Insights

The global fetal bovine serum market is presumed to soar high during the forecast period 2018-2023 owing to the advancements in research and academic initiatives by the private and governmental sector. Market Research Future Reports published their latest report on the global Fetal Bovine Serum Market Share was valued at USD 0.9 billion in 2022 and is projected to grow from USD 0.95 Billion in 2023 to USD 1.3 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.60% during the forecast period (2023 - 2030). 

Fetal bovine serum is a by-product from the beef industry and is a crucial raw material for animal health, biotechnology, pharmaceutical research, and diagnostic as well as other research areas.

Global Fetal Bovine Serum Market: Drivers & Trends

Increase in academic research institutes globally is driving the demand for fetal bovine serum. There have been various governments bodies who are collaborating with academic research institutes to support research activities in pharmaceutical, biotechnology, diagnostics, and veterinary industries as the fetal bovine serum is an essential element for the development of drug and having wide applications in cell-based pharmaceutical research. 

Also, fetal bovine serum (FBS) is also considered to be the most widely used in the growth of cell culture media owing to its high content of embryonic procedures. These abilities of fetal bovine serum are driving to the growth of global fetal bovine serum market. Thus, when it is used at appropriate concentrations, it tends to supply many defined and undefined components that satisfy specific metabolic requirements for the culture of cells.

On the other hand, the advancement in research and academic initiatives by researches is also expected to drive the market growth in positive ways. There has also been observed that the surge in demand from traditional users of serum is also encouraging the market to operate in the years to come. Even the government bodies are investing in more extensive ways to promote and support research activities. This, in turn, is motivating to accelerate the growth of the global fetal bovine serum market in the years to come.

Global Fetal Bovine Serum Market Segmentation

According to the reports published by Market Research Future Reports has mentioned that the global fetal bovine serum market outlook has been segmented by product type, application, and end user.

Wherein, the fetal bovine serum market, by product type is segmented into charcoal stripped, chromatographic, Dialyzed Fetal Bovine Serum (FBS), exosome depleted, stem cell, and others. Added to this, the stem cell is further segmented into embryonic stem cells qualified, and mesenchymal stem cell qualified.

By the mode of application, the fetal bovine serum market has been segmented into drug discovery, cell culture media, in-vitro fertilization, human & animal vaccine production, diagnostics, and others.

By the mode of end user, the market is segmented into research & academic institutes, pharmaceutical, biotechnology, and others.

Regional Outlook 

Region wise, the global fetal bovine serum market has covered the main regions such as Americas, Europe, Asia-Pacific, and the Middle East and Africa. 

It has been observed that North America leads the global fetal bovine serum market owing to the growth of the market in rapid pace attributing to the factors such as an increase in funding events for research, and growing awareness about the high-end fetal bovine serum among medical professionals.

Whereas, Europe currently owes a considerable amount of market share in the fetal bovine serum market. It is observed that, in the near future, the region will predict with exhibiting declination in growth due to emerging ethical issues and religious sentiments about animal-derived products. Such a situation would result in a low market share over the forecast period.

Asia-Pacific is also projected to be the fastest growing region for the global fetal bovine serum market owing to the infrastructural development and increase in outsourcing of research activities to the contract research organizations (CROs) at relatively low cost.

On the other hand, the Middle East and Africa grasp the least share in the global fetal bovine serum market owing to the presence of economically diverse countries, and scarcer initiatives from the government.

Key Players

Market Research Future Reports have listed the names of some of the crucial market players of the global fetal bovine serum market. The names are as follows, HiMedia Laboratories, Merck KGaA, Bovogen Biologicals Pty Ltd, Atlanta Biologicals Inc., TCS Biosciences Ltd, Tissue Culture Biologicals, Rocky Mountain Biologicals, GE Healthcare, Thermo Fisher Scientific, Bio-Techne, PAN-Biotech, Access Biologicals, Animal Technologies Inc., Nucleus Biologics, Biological Industries, Corning Incorporated

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.